Seredol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Seredol

What is Seredol? (Haloperidol Decanoate)

Property Description
Active ingredient Haloperidol Decanoate
Form Long-Acting Injectable Solution (LAI)
Route Intramuscular (IM) Injection
Pharmacological class First-Generation Antipsychotic (Typical Neuroleptic)
Chemical Origin Synthetic Butyrophenone Derivative

What is the Core Identity of Seredol (Haloperidol Decanoate)?

Seredol, whose active ingredient is Haloperidol Decanoate, is a prescription-only medicine classified as a potent First-Generation Antipsychotic (FGA). This class, also known as a typical neuroleptic, is clinically recognized for its strong, focused action in stabilizing severe mental health conditions. The drug belongs to the butyrophenone chemical series and primarily regulates fundamental neurochemical processes.

Composition and Specialized Form of the Injection

The medicine is supplied as a depot preparation, an oily, injectable solution administered exclusively via deep intramuscular (IM) injection. The active compound, Haloperidol, is synthetically modified into a decanoate ester and dissolved in an oil vehicle, typically sesame oil. This specific formulation is the key differentiating factor: it qualifies Seredol as a long-acting injection (LAI). The LAI form is structurally engineered for a prolonged and consistent therapeutic effect, ensuring long-term stability without requiring daily oral administration.

The General Principle of its Action and Benefit

Seredol functions by acting as a powerful Dopamine Antagonist, primarily binding to and blocking the action of dopamine at D2 receptors in the central nervous system. This neurochemical modulation is the foundational way the medicine helps to control and diminish acute symptoms of mental distress. Clinically, this depot form is valued because it maintains consistent therapeutic plasma concentrations over approximately three weeks, ensuring reliable, long-term stability and eliminating the potential variability associated with inconsistent medication adherence. The core benefit of this sustained release mechanism is stability and consistency in managing serious mental health conditions.

Regulatory References

  1. NIH DailyMed: Haloperidol Decanoate Label

What side effects are possible with Seredol?

Possible side effects and safety information

The safety profile of Seredol (Haloperidol Decanoate) is organized by frequency and physiological system, as officially documented in regulatory prescribing information. The most frequently documented adverse reactions, classified as Very Common, relate to movement disorders, known collectively as Extrapyramidal Disorder (e.g., stiffness, tremor, restlessness, or Parkinsonism). Other reactions classified as Common include constipation, dry mouth, and weight increase.


Serious Adverse Reactions

Official labeling highlights the risk of several serious, though less frequent, adverse reactions. These include the potentially fatal symptom complex, Neuroleptic Malignant Syndrome (NMS), which involves fever and severe muscle rigidity. The medicine is also associated with cardiovascular risks, notably QTc interval prolongation and reports of sudden death. Additionally, the risk of developing Tardive Dyskinesia (TD), a potentially irreversible syndrome of involuntary movements, is recognized to increase with the duration of treatment and cumulative dose.


Population-Specific Safety Considerations

Regulatory documents include specific restrictions for certain patient populations. The medicine is not approved for use in elderly patients with dementia-related psychosis due to a documented increased risk of death. Caution is also advised regarding the potential for extrapyramidal and/or withdrawal symptoms in neonates following third-trimester exposure. Furthermore, the label contraindicates use in individuals with pre-existing Parkinson's disease and Dementia with Lewy Bodies, and notes caution due to the potential to lower the convulsive threshold.

Overdose and Emergency Response

The official regulatory profile for Seredol (Haloperidol Decanoate) overdose centers on severe neurological and cardiovascular toxicity. Documented manifestations commonly include pronounced severe extrapyramidal reactions, such as intense rigidity and tremor, alongside marked Central Nervous System depression that may progress to seizures or coma.

The most serious outcomes involve cardiotoxicity. This includes the potential for QTc interval prolongation and a life-threatening arrhythmia known as Torsades de Pointes (TdP), risks which increase at dosages exceeding recommended levels. Profound hypotension and shock are also recognized complications. No specific antidote is known for Seredol overdose; therefore, management requires intensive symptomatic support and continuous monitoring of vital functions.

Government regulatory guidance explicitly mandates that immediate emergency medical attention (911) must be sought if any suspected overdose results in symptoms such as collapse, a seizure, severe difficulty breathing, or the inability to be awakened. Furthermore, regulatory documents advise that epinephrine should not be used if a vasopressor is needed to treat low blood pressure during management. Elderly patients are noted to be more susceptible to cardiovascular risks amplified by overdose.

Therapeutic Uses of Seredol

What Seredol Treats: Main Uses and Benefits

Seredol (Haloperidol Decanoate) is commonly used across conditions characterized by periods of heightened symptoms such as schizophrenia and other chronic psychotic disorders, especially for adults whose care plan involves prolonged supportive antipsychotic therapy. Its therapeutic benefit may assist with maintaining stability and is relevant for easing symptom clusters that may become intense or disruptive, such as hallucinations, delusions, and disorganized thought patterns. This contributes to improved comfort during symptomatic periods and assists with maintaining functional stability.

The specialized long-acting injectable (LAI) formulation is relevant for easing symptom fluctuations by supporting sustained symptom management over an extended period. This approach is generally considered relevant for patients used in situations involving certain distressing symptoms where long-term, consistent symptomatic support is needed, as it helps maintain a sense of stability when symptoms are more noticeable. Seredol is commonly used to help with symptoms that create noticeable physiological strain, such as intense agitation, hostility, and excitement.

“The long-acting formulation supports general well-being during symptomatic phases by providing supportive relief when symptoms interfere with routine activities.”

This medication is applied in addressing symptom clusters that may become intense or disruptive in conditions involving episodic or fluctuating manifestations. By addressing these symptoms, the medicine supports the patient during difficult episodes and assists with maintaining functional stability.

Quick Fact: Relief for Positive Symptoms
This medication is relevant for managing symptoms that interfere with daily comfort, such as hallucinations and delusions, and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility for Seredol (Haloperidol Decanoate) is strictly defined by regulatory documents, primarily allowing use in adult patients (18 years and above) for maintenance treatment after stabilization on oral haloperidol.

Classification Population Restriction
Contraindicated Prohibited in patients with Parkinson’s disease, Dementia with Lewy Bodies, and severe toxic central nervous system (CNS) depression or comatose states.
Contraindicated Prohibited in individuals with certain cardiac risks, including known QTc interval prolongation or uncompensated heart failure. Uncorrected hypokalemia also prohibits use.
Use Not Approved Safety and efficacy have not been established in the pediatric population (under 18 years).
Use Not Approved The medicine is not approved for treating dementia-related psychosis in older adults.
Caution Advised Use requires caution in older adults generally, patients with hepatic (liver) impairment, severe renal (kidney) impairment, or a history of seizures.

Use during pregnancy is permitted only if the potential benefit clearly justifies the potential risk to the fetus, as documented studies are limited. Caution is recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Seredol (Haloperidol Decanoate) is defined by officially documented pharmacokinetic and pharmacodynamic patterns, establishing necessary restrictions for co-administration with other substances.


Official Interaction Restrictions

Classification Interacting Substance/Class Restriction / Formal Outcome
Contraindicated Medicines that Prolong the QTc Interval Co-administration must be avoided due to the increased risk of QTc interval prolongation and serious cardiac events.
Pharmacodynamic Risk Alcohol and CNS Depressants Co-use results in an additive effect, increasing sedation and central nervous system depression. Avoidance is necessary.

Documented Exposure Modification

Interactions that alter the amount of Haloperidol in the body are primarily driven by specific liver enzymes.

  • CYP3A4 and/or CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine) cause a pharmacokinetic interaction that increases Haloperidol exposure and plasma concentrations.
  • CYP3A4 Inducers (e.g., carbamazepine, rifampin) cause a pharmacokinetic interaction that accelerates clearance and decreases the level of Haloperidol.

Other Pharmacodynamic Interactions

Co-administration with Dopaminergic Drugs (e.g., levodopa) may impair the antiparkinson effects of those medicines through receptor antagonism. Additionally, the effects of Seredol may be increased in patients with hepatic impairment due to reduced drug clearance, a population-specific interaction consideration noted in regulatory documents.

Mechanism of Action

Blocking Key Dopamine Receptors in the Brain

Seredol's primary mechanism involves the antagonism (blocking) of Dopamine D2 receptors throughout the Central Nervous System (CNS). This interaction prevents dopamine binding and reduces dopaminergic signal transduction within the mesolimbic and mesocortical pathways, resulting in the modulation of CNS signal activity.

Non-Selective Pathway Modulation

The drug’s D2 antagonism is not selective to a single brain region, impacting the Nigrostriatal and Tuberoinfundibular dopamine pathways. This broad action influences core physiological systems, leading to non-indicational consequences such as alterations to efferent motor pathway signaling and an increase in prolactin release (hyperprolactinemia) via the pituitary gland.

Secondary Receptor Interactions and Physiological Changes

Seredol also engages secondary mechanisms by blocking Histamine H1 and Alpha-1 (alpha1) adrenergic receptors. These secondary interactions contribute to additional physiological adjustments, including CNS depressant effects (via H1 antagonism) and modulation of vascular tone leading to changes in systemic blood pressure (via alpha1 antagonism).

Dosage and Administration Information

Administration Guidelines for Seredol

The correct use of Seredol (Haloperidol) must follow the dosage and procedural instructions provided in prescribing information. The medicine is available in various forms, including oral tablets, a concentrated liquid for oral use, and as two types of intramuscular (IM) injection (lactate and decanoate salts).


Administration Details

Usage Domain Instruction
Route of Administration Oral (tablet, concentrate) or Intramuscular (IM) injection. Do not administer the decanoate injection intravenously.
Dosing Frequency Oral forms are typically taken two or three times daily. IM lactate is given every 4 to 8 hours as needed. The IM decanoate (long-acting) is generally administered once every four weeks.
Dose Adjustment Treatment begins with a low initial dose, followed by gradual dose adjustments (titration) to achieve the lowest effective dose.
Administration Timing Oral forms can be taken with or without food.
Special Preparation The oral liquid concentrate must be measured with the provided dropper and mixed with a beverage (e.g., water, juice, or cola) before immediate consumption.
Age-Specific Rules For geriatric patients and those who are debilitated, lower initial doses and slower dose adjustments are recommended than for non-elderly adults.
Missed Dose If a dose is missed, it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose must be skipped to avoid a double dose.

These instructions establish the method, frequency, and dose-adjustment protocol for using the medicine. This structure ensures that the initial dose is carefully adjusted to the patient's individual needs and that consistent dosing is maintained according to the prescribed regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Seredol (Haloperidol Decanoate)

This summary reviews the structure and findings of research into Seredol, focusing solely on what studies examined and reported, without making any claims about effectiveness or providing clinical advice.


Evidence for Use in Chronic Psychotic Disorders (Maintenance)

The core research for Seredol, which is a long-acting injectable (LAI) form, explores how symptoms change over time in patients with conditions characterized by fluctuating or episodic manifestations, such as schizophrenia. Studies were conducted using Randomized Controlled Trials (RCTs) and observational studies which compared the LAI form to either placebo or the daily oral medication.

These studies focused on outcomes such as symptomatic exacerbation and hospitalization rates. Studies exploring long-term use data show patterns related to a reduced rate of symptomatic exacerbation, particularly when compared to placebo. Research also examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. However, evidence related to global functional measures, such as returning to work or school, is not fully established by all the available controlled trials.


Long-Term Research, Follow-Up, and Durability

The depot nature of Seredol means that researchers place a strong emphasis on long-term outcomes. Many of the key RCTs had follow-up durations that were limited to intermediate periods (e.g., six months to one year). Observational settings offer some perspective on the durability of the response over extended periods, tracking indicators like continuous treatment use and hospitalization rates. However, long-term effects are not fully established, particularly when looking at complex outcomes beyond basic symptom relapse prevention.


What Is Still Uncertain or Remains a Research Gap

Even with the existing body of evidence, the research landscape has defined areas of uncertainty:

  • Comparative evidence is lacking for many direct, controlled comparisons between Seredol and all of the newer long-acting injectable antipsychotics. Much of the evidence comparing these LAIs is derived from settings with varying symptom burdens and study designs, meaning the evidence quality varies across studies.
  • Studies on the LAI form offer limited information for long-term outcomes that track broader functional recovery and social engagement over multiple years.
  • The results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly if their circumstances differ significantly from those in the trials.

Frequently Asked Questions (FAQ)

Common questions about Seredol (FAQ)

Q: How quickly does Seredol start to work after taking a dose?

A: For the long-acting injectable form (Decanoate), the medication gradually builds up in your system. Official information indicates that the concentration of the active ingredient in the blood typically reaches its peak about six days after the injection is administered.


Q: How long does the feeling or effect of Seredol usually last?

A: Seredol (Decanoate) is a long-acting injection specifically formulated for sustained release. This depot preparation is designed to maintain therapeutic effects over approximately three weeks, which aligns with the general recommended dosing interval.


Q: What are the most commonly reported side effects of Seredol in online forums?

A: The most frequently documented adverse reactions in official prescribing information relate to movement disorders, such as stiffness, tremor, and restlessness. Other commonly reported side effects include weight increase, constipation, and dry mouth.


Q: Is it normal to feel a little dizzy or drowsy after starting Seredol?

A: Official information indicates that sedation, drowsiness, and dizziness, particularly a drop in blood pressure when changing posture (orthostatic hypotension), have been reported. These effects are often related to how the medicine acts on the central nervous system.


Q: Can taking Seredol cause weight gain or changes in appetite?

A: Weight increase is documented in regulatory sources as a common adverse reaction associated with this medication.


Q: Are there any serious side effects of Seredol that I should watch out for?

A: The official label highlights the risk of several serious reactions, including Neuroleptic Malignant Syndrome (NMS), which involves severe muscle rigidity and fever. Other serious concerns include a risk of abnormal involuntary movements (Tardive Dyskinesia) and potential heart rhythm issues (QTc interval prolongation).


Q: Can Seredol interact badly with common over-the-counter pain relievers?

A: Regulatory warnings focus on specific drug classes, such as medicines that prolong the QTc interval, central nervous system depressants, and certain liver enzyme inhibitors. Specific interactions with common over-the-counter pain relievers (like ibuprofen or acetaminophen) are generally not detailed in the formal drug interaction warnings.


Q: Is it safe to drink coffee or caffeine while taking Seredol?

A: Regulatory documents advise caution or avoidance when combining this medication with central nervous system (CNS) depressants like alcohol due to additive effects. There is no specific official warning or restriction regarding the intake of caffeine or coffee.


Q: Do alcohol and Seredol interact dangerously?

A: Yes, regulatory warnings state that co-use with alcohol must be avoided. Combining Seredol with alcohol can have an additive effect, significantly increasing sedation and central nervous system depression.


Q: Is it possible for Seredol to make existing anxiety or mood issues worse at first?

A: Although the medication is intended to help stabilize symptoms, official documents list agitation, anxiety, and an exacerbation of psychotic symptoms, including hallucinations, as reported adverse reactions that may occur.


Q: What should I expect during my first week of taking Seredol?

A: Treatment often begins with a low dose and gradual adjustment. During this initial phase, patients may experience common side effects such as drowsiness, dizziness, or movement-related side effects as the body adjusts to the medication.


Q: What is the best time of day to take Seredol?

A: Oral forms are typically taken two or three times daily and may be taken with or without food. The precise timing of administration throughout the day should be determined by the prescribing health professional to best manage individual symptoms.


Q: Why do doctors often start with a very low dose of Seredol?

A: Official treatment protocol advises starting with a low initial dose and using a gradual adjustment process, known as titration. This method is used to slowly find the lowest effective dose needed for the individual patient.


Q: Why do some people say Seredol worked great for them while others had no effect?

A: The response to any medication, including Seredol, can vary significantly among individuals. Official information notes that clinical trial results for a population do not guarantee that every patient will experience the same degree of effectiveness or side effects.


Q: Is there a generic version of Seredol available?

A: Seredol is one brand name for the medication. Its active ingredient is Haloperidol Decanoate, which is generally available as a generic medication from different manufacturers.


Q: Can Seredol affect blood pressure or heart rate?

A: Yes, official labeling states the medication can affect the cardiovascular system. Adverse reactions reported include transient low blood pressure, especially when standing (orthostatic hypotension), and an increased heart rate (tachycardia).


Q: Is Seredol considered a strong medication compared to others in its class?

A: Seredol is formally classified as a potent First-Generation Antipsychotic (Typical Neuroleptic). This means it is recognized for having a strong, focused action in treating severe mental health conditions.


Q: Do people typically take Seredol for long periods, or is it for short-term use?

A: The long-acting injectable form of Seredol is specifically indicated for the maintenance treatment of certain conditions. Its role is for maintenance treatment, suggesting it is often used for prolonged, continuous therapy.


Q: Can Seredol affect sleep patterns, making it harder or easier to sleep?

A: Official prescribing information lists several sleep-related adverse reactions. These include reports of both insomnia (difficulty falling or staying asleep) and lethargy or drowsiness.


Q: Are there special considerations for young adults or teenagers taking Seredol?

A: Official prescribing information states that the safety and effectiveness of Seredol have not been formally established in the pediatric population (under 18 years of age). Any use in this age group would require specific clinical evaluation and guidance.


Q: What happens if I miss a dose of Seredol?

A: For the oral form, the regulatory guidance is usually to skip the missed dose if the next one is near. This is to avoid taking too much. For the long-acting injection (Decanoate), a missed injection should be administered as soon as possible, and the next injection date should be adjusted by the healthcare provider to maintain the correct regimen.


Q: Does Seredol cause any issues if I need to drive or operate machinery?

A: The label advises patients that this medication may affect the ability to perform hazardous tasks, such as driving or operating machinery.


Q: Is Seredol known to be habit-forming or cause dependence?

A: The medication is not classified as a controlled substance and is not typically associated with drug-seeking behavior. Regulatory documents do not contain an explicit statement addressing its potential for physical dependence.


Q: How do people usually feel when they stop taking Seredol?

A: While regulatory texts do not detail adult withdrawal, they include warnings about risks related to changes in the medication, such as the potential for Neuroleptic Malignant Syndrome to recur. Any changes to the treatment regimen should be supervised by a healthcare professional.


Q: Can Seredol cause any skin-related side effects, like a rash?

A: Skin-related reactions have been reported, specifically photosensitivity, which is an increased sensitivity to sunlight. This means sun exposure can potentially lead to severe sunburn or rash, and sun protection is advised.


Q: What happens if Seredol is suddenly stopped without tapering?

A: While specific withdrawal effects in adults are not fully detailed in regulatory documents, the label advises caution regarding abrupt changes in the medication schedule, as this may be linked to certain severe risks.


Q: Can Seredol cause dry mouth or dry eyes?

A: Dry mouth is listed in official documents as a common adverse reaction. While dry eyes are not explicitly listed among the most common effects, dry mucous membranes may occur.


Q: What is the shelf life of Seredol, and how should it be stored?

A: The injection must be stored at controlled room temperature, typically between 15 C and 30 C, and kept protected from light in its original packaging. The specific expiration date, which defines the shelf life, is printed on the package.

How should Seredol be stored and disposed of?

How to Store and Dispose of Seredol?

The storage and disposal requirements for Seredol (Haloperidol Decanoate) injection are defined by regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, between 15° to 30°C (59° to 86°F).
Prohibited Storage Do not refrigerate or freeze the solution.
Protection Keep the ampoule or vial in the original outer carton to protect the contents from light.
Stability The solution must be inspected, and any product that is discolored must be discarded.

Disposal and Safety

This medication must be stored out of the sight and reach of children.

Disposal of unused or expired product must be according to local requirements and is prohibited from being discarded into wastewater or household refuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Seredol found in:

A-Z Index: